ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways

Guohui Wang, Gang Liu, Xiaogang Wang, Seema Sethi, Rouba Ali-Fehmi, Judith Abrams, Ze Zheng, Kezhong Zhang, Stephen Ethier and Zeng-Quan Yang

Abstract

Background: Amplification of the 8p11-12 region has been found in approximately 15% of human breast cancer and is associated with poor prognosis. Previous genomic analysis has led us to identify the endoplasmic reticulum (ER) lipid raft-associated 2 (ERLIN2) gene as one of the candidate oncogenes within the 8p11-12 amplicon in human breast cancer, particularly in the luminal subtype. ERLIN2, an ER membrane protein, has recently been identified as a novel mediator of ER-associated degradation. Yet, the biological roles of ERLIN2 and molecular mechanisms by which ERLIN2 coordinates ER pathways in breast carcinogenesis remain unclear.

Methods: We established the MCF10A-ERLIN2 cell line, which stably over expresses ERLIN2 in human nontransformed mammary epithelial cells (MCF10A) using the pLenti6/V5-ERLIN2 construct. ERLIN2 over expressing cells and their respective parental cell lines were assayed for in vitro transforming phenotypes. Next, we knocked down the ERLIN2 as well as the ER stress sensor IRE1α activity in the breast cancer cell lines to characterize the biological roles and molecular basis of the ERLIN2 in carcinogenesis. Finally, immunohistochemical staining was performed to detect ERLIN2 expression in normal and cancerous human breast tissues.

Results: We found that amplification of the ERLIN2 gene and over expression of the ERLIN2 protein occurs in both luminal and Her2 subtypes of breast cancer. Gain- and loss-of-function approaches demonstrated that ERLIN2 is a novel oncogenic factor associated with the ER stress response pathway. The IRE1α/XBP1 axis in the ER stress pathway modulated expression of ERLIN2 protein levels in breast cancer cells. We also showed that over expression of ERLIN2 facilitated the adaptation of breast epithelial cells to ER stress by supporting cell growth and protecting the cells from ER stress-induced cell death.

Conclusions: ERLIN2 may confer a selective growth advantage for breast cancer cells by facilitating a cytoprotective response to various cellular stresses associated with oncogenesis. The information provided here sheds new light on the mechanism of breast cancer malignancy.

Keywords: Gene amplification, Breast cancer, Endoplasmic reticulum, ERLIN2

Background

Breast cancer cells contain a large number of genetic alterations that act in concert to create the malignant phenotype. For example, the up-regulation of oncogenes, such as Her2, e-MYC and CCND1, directly contributes to the uncontrolled proliferation of breast cancer cells. For cancer cells to survive, they must acquire the ability to tolerate a series of oncogenesis-associated cellular stressors, which include DNA damage, proteotoxic-, mitotic-, metabolic-, and oxidative-stress [1,2]. However, very little is currently known about the genomic basis and molecular mechanisms that allow breast cancer cells to tolerate and adapt to these stresses. Amplification of 8p11-12 occurs in approximately 15% of human breast cancer (HBC). This region of amplification is significantly associated with
disease-specific survival and distant recurrence in breast cancer patients [3-6]. Previous work in our laboratory, together with others, have identified the endoplasmic reticulum (ER) lipid raft-associated 2 (ERLIN2, also known as SPFH2, C8ORF2) gene as one of several candidate oncogenes within the 8p11-12 amplicon, based on statistical analysis of copy number increase and over expression [3,4,7]. Yet, the biological roles of ERLIN2 and molecular mechanisms by which ERLIN2 coordinates ER pathways in breast carcinogenesis remain unclear.

The ER is a cellular organelle primarily responsible for protein folding, lipid and sterol biosynthesis, and calcium storage. Physiological processes that increase protein folding demand or stimuli that disrupt the ER protein folding process can create an imbalance between ER protein folding load and capacity. This imbalance leads to the accumulation of unfolded or misfolded proteins in the ER: a condition referred to as “ER stress” [8,9]. The ER has evolved highly specific signaling pathways, collectively termed the “unfolded protein response” (UPR), to ensure protein folding fidelity and to protect the cell from ER stress. Upon activation of UPR, inositol-requiring protein 1 (IRE1α), the conserved ER stress sensor from yeasts to mammals, mediates splicing of the mRNA encoding X-box binding protein 1 (XBP1). XBP1 serves as a potent UPR trans-activator that helps protein refolding, transportation, and degradation in order to bolster ER capacity and facilitate cell adaptation to stress [8]. However, if UPR fails to restore ER homeostasis, ER stress-associated apoptosis will occur [10]. As part of the UPR program, ER-associated degradation (ERAD) targets aberrantly folded proteins in the ER. In addition to this “quality control” function, ERAD also accounts for the degradation of several metabolically-regulated ER proteins [11].

Recent studies provide evidence that UPR and ERAD components are highly expressed in various tumors, including human breast cancer [12-21]. During tumor development and progression, increased amounts of misfolded proteins caused by gene mutations, hypoxia, nutrient starvation, and high-levels of reactive oxygen species lead to ER stress [22,23]. The activation of UPR and ERAD induces an adaptive response in which the tumor cell attempts to overcome ER stress to facilitate cytoprotection. In this study, we demonstrated that amplification and the resultant over expression of ERLIN2 occurred in both luminal and Her2 subtypes of breast cancer. We also found that the UPR pathway, through the IRE1α/XBP1 axis, modulated the high-level expression of ERLIN2 protein. Furthermore, ERLIN2 had the ability to protect breast cancer cells from ER stress-induced cell death. Thus, ERLIN2 is a novel mediator of ER stress response and thus amplification and over expression of ERLIN2 may facilitate the adaptation of breast cancer cells to the various cellular stresses associated with oncogenesis.

Materials and methods

Cell lines and cell culture conditions

The culture conditions of of SUM breast cancer cells and the immortalized non-tumorigenic MCF10A cells are described in the Additional file 1: Materials and Methods.

Genomic array CGH

Genomic array CGH experiments were performed using the Agilent 44 K human genome CGH microarray chip (Agilent Technologies, Palo Alto, CA). Agilent’s CGH Analytics software was used to calculate various measurement parameters, including log2 ratio of total integrated Cy-5 and Cy-3 intensities for each probe.

Semiquantitative RT-PCR reactions

Total RNA was prepared from human breast cancer cell lines and the MCF10A cell line by standard methods [3,24]. For RT-PCR reactions, RNA was converted into cDNA via a reverse transcription reaction using random hexamer primers. Primers were ordered from Invitrogen (Carlsbad, CA). A GAPDH primer set was used as a control. Semiquantitative RT-PCR was done using the iQSYBR Green Supermix (Bio-Rad, Hercules, CA).

Lentivirus construction and transduction of cells

The lentiviral expression construct containing the ERLIN2 gene (pLenti-ERLIN2), was established as previously described [3]. The lentivirus for pLenti-ERLIN2 was generated and used to infect the immortalized, non-transformed mammary epithelial MCF10A cells. Control infections with pLenti-LacZ virus were performed in parallel with the pLenti-ERLIN2 infections. Selection began 48 h after infection in growth medium with 10 μg/mL blasticidin in the absence of either insulin or epidermal growth factor (EGF). Upon confluence, selected cells were passaged and serially cultured.

Three-dimensional morphogenesis assays in Matrigel

For three-dimensional morphogenesis assays in Matrigel, cells grown in monolayer culture were detached by trypsin/EDTA treatment and seeded in Matrigel (BD Biosciences, San Jose, CA) precoated 8-well chamber slides. The appropriate volume of medium was added and cells were maintained in culture for 10–18 days. Phase-contrast images and immunostaining images were taken using bright-field and confocal microscopy.
Lentivirus-mediated shRNA knockdown of gene expression

We knocked down the expression of the human ERLIN2 gene in breast cancer cell lines and in the MCF10A cell line using the Expression Arrest GIPZ lentiviral shRNA-mir system (OpenBiosystems, Huntsville, AL). Lentivirus was produced by transfecting 293FT cells with the combination of the lentiviral expression plasmid DNA and Trans-Lentiviral packaging mix (OpenBiosystems, Huntsville, AL). For cell infection, viral supernatants were supplemented with 6 μg/mL polybrene and incubated with cells for 24 hours. Cells expressing shRNA were selected with puromycin for 2–3 weeks for functional studies (cell proliferation and colony formation assays) and for 4 to 10 days after infection for RNA extraction.

Recombinant adenoviral or retroviral infection

Adenovirus vectors for expressing flag-tagged IRE1α isoforms, including wild type IRE1α (Ad-IRE1α WT), IRE1α kinase mutant (Ad-IRE1α K599A), and IRE1α RNase mutant (Ad-IRE1α K907A), were kindly provided by Dr. Yong Liu (Institute for Nutritional Sciences, Shanghai, China) and amplified using the AdEasy System (Stratagene) [25,26]. Retrovirus expressing spliced XBP1 was kindly provided by Dr. Lauri Glimcher (Harvard University) [27]. For infection of cells with adenovirus and retrovirus, cells were seeded in six-well plates. After 24 h, cells were infected with adenovirus expressing wild type IRE1α (Ad-IRE1α WT), IRE1α kinase mutant (Ad-IRE1α K599A), IRE1α RNase mutant (Ad-IRE1α K907A), and retrovirus expressing spliced XBP1 as described previously [28,29].

Tissue array and immunohistochemistry (IHC) staining

Human breast cancer tissue array was obtained from Nuclea Biotechnologies (Pittsfield, MA). Immunohistochemistry was performed on tumor tissue sections using the standard laboratory protocols [30]. Briefly, after deparaffinizing and hydrating with phosphate-buffered saline (PBS) buffer (pH 7.4), the sections were pretreated with hydrogen peroxide (3%) for 10 minutes to remove endogenous peroxidase, followed by antigen retrieval via steam bath for 20 minutes in EDTA. A primary antibody was applied, followed by washing and incubation with the biotinylated secondary antibody for 30 minutes at room temperature. Detection was performed with diaminobenzidine (DAB) and counterstaining with Mayer hematoxylin followed by dehydration and mounting. Immunostained slides were blindly evaluated under a transmission light microscope. Areas of highest staining density were identified for evaluating the expression in tumors.

Results

ERLIN2 is amplified and over expressed in human breast cancer cells

Recently, we used quantitative genomic PCR and array comparative genomic hybridization (CGH) to profile copy number alterations in 10 human breast cancer cell lines and 90 primary human breast cancers [3,6,31]. Analysis of our array CGH data showed that ERLIN2 gene was commonly amplified in 30% of the cell lines tested, as well as in 7.8% of breast cancer specimens tested (Figure 1a). Previously, we and several other laboratories have demonstrated that the 8p11-12 amplicon occurs mainly in the luminal subtype of breast cancer cells, such as the SUM-44 and SUM-52 cell lines. However, SUM-225 is a Her2-amplified HBC cell line [31,32]. We also found two primary tumors, 10173 and 9895, which have Her2 gene amplifications in addition to the amplification of the ERLIN2 gene (Figure 1a). To obtain further support for a potential involvement of the ERLIN2 region in breast cancer, we searched the published database of the Affymetrix 250 K array CGH [33]. We found that 42 of the 243 HBC lines and primary samples in the array exhibited amplification of the ERLIN2 region. Interestingly, eight of the ERLIN2-amplified samples showed co-amplification of the Her2 gene (Additional file 1: Figure S1). Next, we measured ERLIN2 protein levels in ten breast cancer cell lines by Western blot analysis. In correlation with ERLIN2 gene amplification, ERLIN2 protein levels in SUM-44, SUM-52, and SUM-225 cells were dramatically greater than the levels in breast cancer cell lines without ERLIN2 gene amplification (Figure 1b). The presence of the ERLIN2 amplification in both luminal and Her2 subtypes of breast cancer prompted us to further investigate the role of the ERLIN2 gene in breast cancer progression.

ERLIN2 plays a functional role in breast cancer cells

Next, we addressed whether ERLIN2 possess transforming properties. We transduced the immortalized, non-transformed mammary epithelial cell line, MCF10A, with lentivirus expressing ERLIN2 or control LacZ. Semi-quantitative RT-PCR (qRT-PCR), Western blot and immunofluorescence staining confirmed the over expression of ERLIN2 protein in MCF10A-ERLIN2 cells (Figure 2a and Additional file 1: Figure S2). The infected MCF10A cells were then subjected to analyses for growth rates, growth factor-independent proliferation, anchorage-independent growth, and three-dimensional morphogenesis assays. Growth curves and colony formation assays in MCF10A cells showed that forced expression of ERLIN2 resulted in growth factor-independent proliferation in insulin-like growth factor-deficient media. To further examine the effects of ERLIN2 in a context that more closely resembles in vivo mammary architecture, we assessed the consequences of ERLIN2
over expression on three-dimensional morphogenesis in Matrigel. Although MCF10A cells formed polarized, growth-arrested acinar structures with hollow lumens similar to the glandular architecture in vivo, MCF10A-ERLIN2 cells formed abnormal acini at a high frequency that was grossly disorganized, and contained filled lumens (Figure 2b).

To further explore the pathophysiological function of ERLIN2 over expression, we stably silenced the ERLIN2 gene in SUM-44 and SUM-225 breast cancer cells using the lentiviral-based shRNA system. To perform RNAi knockdown experiments, we utilized pGIPZ-ERLIN2 shRNA expression constructs in which TurboGFP and shRNA were part of a bicistronic transcript allowing for the visual marking of the shRNA-expressing stable cells. qRT-PCR and Western blot analysis indicated a marked reduction in expression levels of ERLIN2 mRNA and protein in the stable ERLIN2-shRNA-transduced SUM-44 and SUM-225 cell lines as compared with the control cell lines infected with a non-silencing shRNA lentiviral control (Figure 3a). Among the two targeted vectors used, ERLIN2-shRNA vector #1 produced a more striking knockdown effect: infected SUM-225 cells had a nearly complete loss of ERLIN2 protein expression (Figure 3a). We did not detect any change in ERLIN1 mRNA and protein levels in ERLIN2-shRNA knockdown cells, thus ruling out the possibility of off-target effects by ERLIN2-shRNAs (Data not shown). Cell growth and proliferation analyses showed that knockdown of ERLIN2 in SUM-44 and SUM-225 cells also suppressed anchorage-independent growth in soft agar, one of
the hallmark characteristics of aggressive cancer cells. (Figure 3c). Taken together, results from over expression and knockdown experiments suggested ERLIN2 plays a role in cell proliferation and maintenance of transforming phenotypes in breast cancer cells with the 8p11-12 amplification.

Expression of ERLIN2 is regulated by the ER pathway through IRE1α/XBP1

Recent studies have identified ERLIN2 both as a novel component of lipid raft domains in the ER membrane and as a substrate recognition factor during ERAD of activated inositol triphosphate receptors (IP3R) as well as other substrates [34-36]. IRE1α is the primary ER stress sensor implicated in the regulation of the ERAD pathway [37]. Under ER stress, IRE1α undergoes auto-phosphorylation to activate its RNase activity, which triggers one of the UPR cascades through splicing Xbp1 mRNA [8]. Previous work has demonstrated that breast cancer cells over express XBP1 [38,39], while we observed that SUM-44, SUM-52 and SUM-225 cell lines over expressed total and activated XBP1 (Additional file 1: Figure S3 Additional file 2: Table S1). To evaluate the possibility of an association between ERLIN2 expression and the IRE1α-mediated UPR pathway in HBC, we inhibited IRE1α RNase or kinase activity in breast cancer cells. To accomplish this, we used adenoviral-based expression system to introduce the previously characterized IRE1 kinase dominant-negative mutant (IRE1 K599A) or the IRE1 RNase dominant-negative mutant (IRE1 K907A) into breast cancer cells [26,40,41]. We chose SUM-44 cells for this experiment because the SUM-44 cells are very amenable to adenovirus-mediated expression. The inhibition of the IRE1α RNase activity significantly reduced protein levels of ERLIN2 in SUM-44 cells (Figure 4a). In addition, forcible expression of wild-type IRE1α or spliced XBP1 in MCF10A cells resulted in increased expression levels of endogenous ERLIN2 protein (Figure 4b and c). However, quantitative real-time RT-PCR analysis showed that over expression of IRE1α or spliced XBP1 did not increase expression of the ERLIN2 mRNA (Data not shown). Next, we asked whether ERLIN2 expression was induced by stress inducers in normal mammary epithelial cells. Our group routinely cultures MCF10A cells in serum-free, growth factor-supplemented media. Oncogenesis-associated conditions, such as nutrient or growth factor depletion, can cause pathophysiologic ER stress [22,23]. When MCF10A cells were cultured in media lacking insulin or EGF, expression levels of endogenous ERLIN2 protein in MCF10A were increased as compared with levels in cells cultured in normal media (Figure 4d). Our observations
Figure 3 shRNA-mediated knockdown of ERLIN2 inhibits monolayer and anchorage-independent cell growth in breast cancer cells with ERLIN2 amplification. (a) Knockdown of ERLIN2 expression in SUM-44 and SUM-225 cells with two different shRNAs was confirmed by western blot. (b) In vitro growth rate of SUM-44 and SUM-225 cells with ERLIN2 shRNA treatment compared to cells with control shRNA treatment. (c) Knockdown of ERLIN2 reduces colony formation in soft agar. SUM-44 and SUM-225 cells were transfected with ERLIN2 shRNA#1 or control shRNA. The colony numbers were counted 3 weeks later (P < 0.05).
suggest that the ER stress pathway likely regulates ERLIN2 protein expression through IRE1α-activated XBPI in human breast epithelial cells.

ERLIN2 promotes breast cancer cell survival
Next, we tested if amplification and over expression of ERLIN2 enhances the resistance to a variety of stressors to promote cancer cell survival. Figure 5a shows the IC_{50} values for the ER stress-inducing reagent Tunicamycin (Tm), in ten breast cancer cell lines as well as in the nontransformed human mammary epithelial cell line MCF10A. SUM-44 and SUM-225 cells, which have ERLIN2 amplification, had significantly higher TM IC_{50} values than cell lines without ERLIN2 amplification (P < 0.05). We obtained similar results with Thapsigargin (Tg) treatment of SUM-225 cells (data not shown). Expression of the CCAAT/enhancer-binding protein (C/EBP) homology protein (CHOP) is characteristic of the ER stress-mediated apoptotic pathway. In response to treatment with Tm or Tg, expression of CHOP dramatically increased in control MCF10A cells (Figure 5b). However, induction of CHOP by Tm and Tg treatment was weaker or barely detectable in SUM-44 and SUM-225 cells (Figure 5b). Next, to determine whether suppressing ERLIN2 in breast cancer cells re-sensitize them to ER-stress, we challenged stable ERLIN2-knockdown SUM-44 and SUM-225 cells with Tm and Tg for 72 hours and evaluated their viability using the MTT assay. Knockdown of ERLIN2 resulted in increased sensitivity to Tm or Tg-induced cell death (Figure 5c). Our data suggested that over expression of ERLIN2 may facilitate the adaptation of breast epithelial cells to ER stress by supporting cell growth. Future investigations are required to more precisely address the mechanism by which ERLIN2 promotes breast cancer cell survival.

Expression of ERLIN2 in breast tissues: Carcinomas and normal
We evaluated the expression of ERLIN2 in normal and cancerous human breast tissues using immunohistochemistry (IHC) in breast cancer tissue arrays. We first confirmed the specificity and sensitivity of the ERLIN2 antibody for visualizing ERLIN2 expression in formalin-fixed, paraffin-embedded breast cancer cell lines. Consistent with the immunoblotting data, SUM-225 cells displayed significantly higher levels of positive staining as compared with the MCF10A control cells (Additional file 1: Figure S4). The tissue array included 34 breast tissues: 20 carcinomas and 14 normal tissues. Figure 4a shows representative images of ERLIN2 expression in normal and carcinoma tissues. The ERLIN2 antibody stained positively in normal tissues, whereas it was strongly stained in carcinomas (Figure 4a).
carcinomas and 17 normal breast tissue, which included 14 cases of adjacent normal counterparts. ERLIN2 expression was scored based on the staining intensity: 0 (negative), 1+ (weak), 2+ (low); 3+ (moderate) or 4+ (strong). In breast carcinomas samples, 11 (32.4%) stained ERLIN2 strongly and 13 (38.2%) moderately...
gene amplification was in vivo and in vitro et al. BMC Cancer
mRNA level, suggesting in vivo α under ER stress, up-regulated expression of the gene
and is not tumorigenic [48]. In contrast, Her2 RNase activation of the gene
plays a role in cell proliferation and maintenance of these substrates [34,35].

Of particular interest in this study, we found that the UPR pathway modulated ERLIN2 protein expression in breast cancer cells through the IRE1α/XBP1 axis. Forced expression of IRE1α, or spliced XBP1, the target of IRE1α under ER stress, up-regulated expression of the ERLIN2 protein, while knockdown of IRE1α RNase activity decreased ERLIN2 expression in the ERLIN2-amplified breast cancer cells. These gain- and loss-of-function studies provided support that the IRE1α/XBP1-mediated UPR pathway in HBC regulated production of ERLIN2. Importantly, our study also showed that the depletion of nutrient and growth signals, a condition that is associated with oncogenesis and ER stress, can increase ERLIN2 production in breast epithelial cells. However, over expression of IRE1α or spliced XBP1 did not increase expression of the ERLIN2 mRNA level, suggesting regulation at the post-transcription level. In the present study, we also showed that expression of primary breast cancer cells significantly up regulated ERLIN2 protein expression as compared with normal breast cells. As we had described earlier, amplification of the ERLIN2 gene, as part of the 8p11-12 amplicon, occurs in approximately 15% of human breast cancer. It is reported that XBP1 is over expressed in aggressive breast cancer and associated with cancer cell survival and therapy resistance [51]. In the ten SUM breast cancer cell lines we investigated, three lines have both ERLIN2 gene amplification and up-regulation of activated XBP1, resulting in dramatically high-level expression of ERLIN2 protein. In contrast, two lines with up-regulation of the XBP1, but no ERLIN2 gene amplification, had moderately high-expression of the ERLIN2 protein. Taken together, our results raise an intriguing notion that the breast cancer cells may utilize gene amplification and the UPR pathway to regulate ERLIN2 protein over-production under oncogenic stress conditions.

In response to ER stress, cells activate UPR to program gene transcription and translation. Depending on the type and/or degree of the stress, cells can differentially activate the UPR pathways in order to make survival or death decisions [52]. The literature indicates that the UPR branch, through IRE1α/XBP1, plays a critical role in cell adaptation to ER stress by increasing protein refolding and degradation of misfolded proteins, and by bolstering the protein-folding capacity and

Discussion
The 8p11-12 amplicon in HBC has been the subject of a number of studies using high-resolution genomic analysis of copy number and gene expression [3-6,42,43]. We previously found that the 8p11-12 amplicon has a highly complex genomic structure and that the size of the amplicon in three HBC lines, SUM-44, SUM-52 and SUM-225, is highly variable [6,31]. Moreover, the sub-amplicon of 8p11-12 that carries the ERLIN2 gene amplification was more frequently identified in HBCs [4,7]. Previous studies have demonstrated that the 8p11-12 amplicon occurs mainly in the luminal subset of breast cancer cells, such as SUM-44 cells, a subset that also expresses the estrogen receptor [3,4,7,44-46]. Here we report that the co-amplification of the ERLIN2 region occurred in a subset of HER2-amplified breast cancer cells, including SUM-225 cells. Our recent studies with Her2 model cells demonstrated that over expression of Her2 alone is not sufficient to induce full transformation in vitro and is not tumorigenic in vivo [47]. In contrast, Her2-amplified SUM225 breast cancer cells are fully transformed in vitro and tumorigic in vivo [48]. In this study, in vitro transforming and shRNA assays provided evidence that ERLIN2 is the most likely non-classical oncogene within this 8p11-12 minimal common amplified region. Our results suggest that the ERLIN2 plays a role in cell proliferation and maintenance of transforming phenotypes in breast cancer cells with the 8p11-12 amplification.

ERLIN2 belongs to a larger family of proteins that share an evolutionarily conserved stomatin/prohibitin/flotillin/HK/C (SPFH) domain. SPFH-containing proteins localize to different membranes, but have common characteristics. For example, N-terminal sequences are required for subcellular localization and membrane attachment, while the coiled-coil motifs located at the C-terminal side of SPFH domain mediate the assembly of high-molecular-weight complexes [49]. ERLIN2 and its homologue ERLIN1 were originally identified as components of lipid rafts that localize to the ER [36]. More recently, ERLIN2 has been recognized as a novel mediator of ERAD [34,36,50]. ERLIN2 binds to activated IP3Rs and other ERAD substrates, leading to polyubiquitination and subsequent degradation of these substrates [34,35].

Figure 6 Immunohistotochemical staining of ERLIN2 protein on a representative HBC sample and a normal control.
secretion potential of the ER [20,52,53]. Cancer cells may adapt to the cellular stress and evade stress-induced apoptotic pathways by differentially activating the UPR branches. Indeed, tumor microenvironment has been characterized by a ‘baseline’ level of ER stress response that promotes tumor development and metastasis [20].

Conclusions
In the present study, we show that over expression of ERLIN2 may facilitate the adaptation of breast epithelial cells to ER stress by supporting cell growth and protecting the cells from ER stress-induced apoptosis. These results suggest that ERLIN2 confers a selective growth advantage for breast cancer cells by facilitating a cytoprotective response to various cellular stresses associated with oncogenesis. The information provided here sheds new light the mechanism of breast cancer malignancy.

Additional files

**Additional file 1: Materials and Methods [54-58].**

**Additional file 2: Table S1.** Expression Levels of XBP1, ERLIN1 and ERLIN2 in Ten SUM Breast Cancer Lines Using Our Affymetrix Array Database. Table S2: Expression of ERLIN2 in breast tissues/carcinomas and normal. Figure S1. Figure S2. Figure S3. Figure S4. Figure S5.

Abbreviations
Her2: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; neuro/glialblastoma derived oncogene homolog (avian); c-MYC: v-myc myelocytomatosis viral oncogene homolog (avian); CCND1: cyclin D1; HBC: Human breast cancer; ER: Endoplasmic reticulum; ERLIN2: Endoplasmic reticulum lipid raft-associated 2; UPR: Unfolded protein response; IRE1: Insolito-requiring protein 1; XBP1: X-box binding protein 1; ERAD: ER-associated degradation; CGH: Comparative genomic hybridization; shRNA: Short hairpin RNA; IP3R: Insolito triphosphate receptors; Tm: Tunicamycin; Tg: Thapsigargin; CHOP: The CCAAT/enhancer-binding protein (C/EBP) homology protein; IHC: Immunohisyochemistry.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
GHW, GL and XGW performed most of the experiments, participated in designing the study, analyzing the data. SS, RA and ZZ were involved in IHC staining experiments. SE participated in design of the study. KZZ and ZQY conceived, coordinated, designed and procured funding for the study and wrote the manuscript. All authors gave final approval for the manuscript to be published.

Acknowledgements
This work was supported by the Department of Defense Breast Cancer Program grants BC083945 and BC09179P1 to Kezhong Zhang, the National Institutes of Health (NIH) grant 1R21ES017829 to Stephen P. Ethier, and a Karmanos Cancer Institute pilot grant to Zeng-Quan Yang and Kezhong Zhang. The array CGH work was facilitated by the Microarray and Bioinformatics Core Facility of the Wayne State University Environmental Health Sciences Center, NIHES P30 ES06639. The Biorepository core and the Biotistics Core of the Karmanos Cancer Institute are supported by the National Institutes of Health grant P30-CA022453-29. We thank Michele L. Dzibuniski and Katie L. Streicher for technical assistance on the cell culture and three-dimensional morphogenesis assays. We thank Dr. Alicia Bollig-Fischer and Kimberly Lyons for discussions and careful reading of a draft manuscript.

Author details
1Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
2Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, USA. 1Department of Oncology, Wayne State University, Detroit, MI 48201, USA. 2Department of Pathology, Wayne State University, Detroit, MI 48201, USA. 1Department of Immunology and Microbiology, Wayne State University, Detroit, MI 48201, USA. 3Biorepository Core, Wayne State University, Detroit, MI 48201, USA. 3Biostatistics Core of the Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. 1Department of Medical Imaging and Interventional Radiology, State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, No. 651, Dongfeng Road East, Guangzhou, 510065, China. 1Department of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, BEB 412, 68 President St, Charleston, SC 29425, USA.

Received: 28 November 2011 Accepted: 14 May 2012 Published: 8 June 2012

References
1. Luo J, Sollimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(5):823–837.
2. Sollimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130(6):886–898.
3. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple interacting oncogenes on the 8p11-12 amplicon in human breast cancer. Cancer Res 2006, 66(24):11632–11643.
4. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, Lenteisser A, Giniatier C, Morvillle F, et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Molecular cancer research: MCR 2005, 3(12):655–667.
5. Garcia MJ, Pole JC, Chin SF, Teschendorff A, Martinez-Climent JA, Fridlyand J, Albertson DG. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009 ;
6. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007, 8(7):519–529.
7. Zhang K, Kaufman RJ: From endoplasmic-reticulum stress to the inflammatory response. Nature 2008, 454(7203):455–462.
8. Zhang K, Kaufman RJ: Identification and characterization of endoplasmic reticulum stress-induced apoptosis in vivo. Methods Enzymol 2008, 442:395–419.
9. Schroder M, Kaufman RJ: ER stress and the unfolded protein response. Mutat Res 2005, 569(1-2):229–63.
10. Dong D, Ni M, Li J, Xiong S, Ye W, Virey JJ, Mao C, Ye R, Wang M, Pen L, et al. Critical role of the stress chaperone GRP78/Bip in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 2008, 68(24):998–505.
11. Pyroko P, Schonthal AH, Hofman FM, Groshen S, Lieskovsky G, Skinner DG, et al. Glucose-regulated protein GRP78 is upregulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 2007, 38(10):1547–1552.
12. Dongfeng Road East, Guangzhou, 510065, China.
13. Pyrko P, Schonthal AH, Hofman FM, Groshen S, Lieskovsky G, Skinner DG, et al. Glucose-regulated protein GRP78 is upregulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 2007, 38(10):1547–1552.
14. Terlin-1 is overexpressed on the tumor cell surface and enables chemosensitivity in malignant gliomas. Cancer Res 2007, 67(20):9889–9816.
15. Daneshmand S, Quel M, Li Y, Xiong S, Ye W, Virey JJ, Mao C, Ye R, Wang M, Pen L, et al. Critical role of the stress chaperone GRP78/Bip in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 2008, 68(24):998–505.
16. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS: The unfolded protein response regulator GRP78/Bip as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007, 67(20):9889–9816.
17. Dashehand S, Quel M, Li Y, Xiong S, Ye W, Virey JJ, Mao C, Ye R, Wang M, Pen L, et al. Critical role of the stress chaperone GRP78/Bip in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 2008, 68(24):998–505.
18. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS: The unfolded protein response regulator GRP78/Bip as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007, 67(20):9889–9816.
19. Hetz C: The UPR as a survival factor of cancer cells: More than folding proteins? Leuk Res 2009, 33:1103–1110.
to tumor-associated endothelial cells. Molecular cancer research: MCR 2008, 6(8):1268–1275.
19. Morner M, Pluquet O, Bouchecairel M, Chevet E. Integrated endothelial
luminal copy number alterations in breast tumor cell lines. Breast Cancer Res 2003, 5(6):530–536.
20. Wang G, Yang ZQ, Zhang K. Endothelial luminal copy number
response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res 2010, 2(1):65–74.
21. Tsai YC, Weissman AM. The Unfolded Protein Response, Degradation from
Endoplasmic Reticulum and Cancer. Genes Cancer 2010, 1(7):764–788.
22. Healy SJ, Gorman AM, Mousavi-Shafiei P, Gupta S, Samal A. Targeting
the Endoplasmic reticulum-stress response as an anticancer strategy.
Eur J Pharmacol 2009, 625(1–3):234–246.
23. Bukowski DT, Hegele PS. Regulation of basal cellular physiology by the
homeostatic unfolded protein response. J Cell Biol 2010, 189(5):783–794.
24. Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Inamura M, Sugano S, Nakamura Y, Inazawa J. Identification of a novel gene, GASC1,
within an amplicon at 9p23–24 frequently detected in esophageal cancer cell lines. Cancer Res 2000, 60(17):4735–4739.
25. Qiu Y, Mao T, Zhang Y, Shao M, You J, Jin Q, Chen Y, Wu D, Xie D, Lin X, et al. A crucial role for RACK1 in the regulation of glucose-stimulated
IRE1alpha activation in pancreatic beta cells. Sci Signal 2010, 3(160):ra7.
26. Pole JC, Courty-Cahen C, Garcia MJ, Blood KA, Cooke SL, Atlop AE, Tse DM, Caldas C, Edwards PA. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 2006, 25(15):5693–5706.
27. Haverty PM, Fridlyand J, Li L, Getz G, Bermanik R, Lorth S, Wu TD, Cavet G, Zhang Z, Chant J. High-resolution genomic and expression analyses of
copy number alterations in breast tumors. Genes Chromosomes Cancer 2008, 47(6):530–542.
28. Holland DG, Burleigh A, Git A, Goldsgrabner M, Perez-Mancera PA, Chin SF, Hurtado A, Bruna A, Ali HR, Greenwood W, et al. ZNF703 is a common
Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 2011, 3(3):167–180.
29. Sircouilomb F, Nicolas N, Ferrari A, Finetti P, Behrouiseh I, Rousset E, Lounigo A, Adeladje J, Baudelet E, Esteses Y, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 2011, 3(3):153–166.
30. Chin K, DeVries S, Fridlyand J, Spellman PT, Ruedagaokrupa R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations
linked to breast cancer pathophysiology. Cancer Cell 2006, 10(3):529–541.
31. Woods Ignatoski KM, Zubilinski ML, Ammermann C, Ethier SP. Cooperative
interactions of HER-2 and HPV-16 oncoproteins in the malignant
transformation of human mammary epithelial cells. Neoplasia 2005, 7(8):788–798.
32. Behbod F, Kretelli FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young
et al. Intratumoral integrin alpha-v beta-3 expression and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer Res 2003, 5(6):530–536.
33. Qiu Y, Mao T, Zhang Y, Shao M, You J, Jin Q, Chen Y, Wu D, Xie D, Lin X, et al. A crucial role for RACK1 in the regulation of glucose-stimulated
IRE1alpha activation in pancreatic beta cells. Sci Signal 2010, 3(160):ra7.
34. Poole JC, Courty-Cahen C, Garcia MJ, Blood KA, Cooke SL, Atlop AE, Tse DM, Caldas C, Edwards PA. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 2006, 25(15):5693–5706.
35. Haverty PM, Fridlyand J, Li L, Getz G, Bermanik R, Lorth S, Wu TD, Cavet G, Zhang Z, Chant J. High-resolution genomic and expression analyses of
copy number alterations in breast tumors. Genes Chromosomes Cancer 2008, 47(6):530–542.
36. Holland DG, Burleigh A, Git A, Goldsgrabner M, Perez-Mancera PA, Chin SF, Hurtado A, Bruna A, Ali HR, Greenwood W, et al. ZNF703 is a common
Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 2011, 3(3):167–180.
37. Sircouilomb F, Nicolas N, Ferrari A, Finetti P, Behrouiseh I, Rousset E, Lounigo A, Adeladje J, Baudelet E, Esteses Y, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 2011, 3(3):153–166.
38. Chin K, DeVries S, Fridlyand J, Spellman PT, Ruedagaokrupa R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations
linked to breast cancer pathophysiology. Cancer Cell 2006, 10(3):529–541.
39. Woods Ignatoski KM, Zubilinski ML, Ammermann C, Ethier SP. Cooperative
interactions of HER-2 and HPV-16 oncoproteins in the malignant
transformation of human mammary epithelial cells. Neoplasia 2005, 7(8):788–798.
40. Behbod F, Kretelli FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young
et al. Intratumoral integrin alpha-v beta-3 expression and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer Res 2003, 5(6):530–536.